

Newton Biosafety Committee Member Bio's (2018-2019)

Thekla Diehl

Thekla Diehl is a Senior Research Grant Administrator / Financial Specialist at Partners Health Care, where 60% of her portfolio are National Institute of Health grants.

Her undergraduate focus was Biochemistry and Genetics. After graduating from the University of Cape Town in South Africa with a Masters in Medical Biochemistry, she left for Europe in protest of the apartheid system.

Upon arrival in America in the early eighties she worked in the laboratory at the Harvard teaching hospitals for over twenty year, first as a scientist and later as a laboratory manager.

After obtaining a MBA at the Simons School of Management, her focus shifted from the laboratory to the business side of science.

She has been a resident of Newton for the past thirty years, where she lives with her husband and her two boys, who graduated through the Newton Public School.

William Dietrich

Dr. William Dietrich's is a biologist/pharmacologist whose work has focused on creative interdisciplinary collaborations aimed at large scientific problems such as the Genome Project, genetic determinants of host susceptibility to infectious disease, and drug discovery. His current position is as Executive Director of Discovery and Translational Pharmacology in the Disease Area X department at Novartis Institutes of BioMedical Research in Cambridge. He is a co-author/inventor on more than 60 scientific publications and patents, and has led or performed IND-enabling pharmacology research for 6 different drug discovery programs.

Gary du Moulin

Gary C. du Moulin, Ph.D., M.P.H. is a life-long resident of Newton, graduate of Newton High School and a professional microbiologist by training. Dr. du Moulin completed a career as Vice President of Quality Operations at Genzyme Biosurgery and Sanofi where he participated in the development and execution of quality systems for Genzyme's products including biologics and cell-based therapies. Prior to his industrial experience, Dr. du Moulin was Assistant Professor of Anesthesia (microbiology) at the Harvard Medical School in the Department of Anesthesia at Beth Israel Hospital and has more than 150 publications in the areas of microbiology, epidemiology, biosafety and the regulation and quality control of living cells as a therapeutic modality. Dr. du Moulin has served on the U.S. Pharmacopoeia's General Chapters Biological Analysis Expert Committee as well as the Scientific and Medical Research Funding Working Group for the California Institute of Regenerative Medicine and has taught at the Massachusetts College of Pharmacy and Health Sciences University. He is retired from the U.S. Army Reserve at the rank of Colonel after 38 years of service.

Ted Marple

Ted has worked in the health care industry for over 20 years. Most recently as CEO of a Contract Research Organization based in Worcester, MA. Prior to that, he led the business operations at a biomanufacturing technology company that was acquired by GE. He was worked at biotech and large pharma companies leading business development efforts, and has broad experience in strategy, development and operations for life science companies.

Aric Parnes

Aric Parnes, MD, is a staff hematologist at Dana-Farber Cancer Institute and Brigham and Women's Hospital focusing on bleeding disorders and premalignant hematology. He has lived in Newton since 2010 with his wife and four-year old twins. He serves on the Newton Health Advisory Council and Biosafety Committee.

John "Jay" Schwartz

Dr. Schwartz received his Ph.D. in Biochemistry and Molecular Biology at New York Medical College and was a Post-doctoral fellow at the M.I.T. Department of Biology / Harvard Medical School. He served as a lab head as Research Scientist Faculty at the M.I.T. Center for Biomedical Engineering. The CEO, Dr. John 'Jay' Schwartz, was co-founder of engeneOS, Inc. a venture-backed bio-nanotechnology company with a highly successful exit through acquisition. Prior to joining AcuityBio, he was a consultant in his capacity as Director of Life Sciences at Stage1 Strategies, LLC, a strategy and management-consulting firm focused on assisting emerging technology and early stage companies to develop, grow and achieve exits for investors through strategic acquisition with large pharmaceutical companies.

Karl Munger

Karl Munger is a Professor in the Department of Developmental, Molecular and Chemical Biology at Tufts University School of Medicine, Boston, MA. He holds a Ph.D. in Biochemistry from the University of Zurich, Switzerland followed by postdoctoral training at the National Institutes of Health in Bethesda, MD. He is an accomplished academic researcher with over 25 years of experience as an independent biomedical researcher. His research group investigates how infections with human papillomaviruses (HPV) contribute to human cancers. He has published more than 200 scientific articles and holds two US patents. He has lived in Newton for over 20 years.